美国食品药品监督管理局的获益-风险评估：寻求平衡 - Suppr

Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance.

作者信息

Califf Robert M

机构信息

Formerly with the US Food and Drug Administration, Silver Spring, Maryland.

出版信息

JAMA. 2017 Feb 21;317(7):693-694. doi: 10.1001/jama.2017.0410.

DOI:10.1001/jama.2017.0410

PMID:28114599

Abstract

摘要

相似文献

Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance.

JAMA. 2017 Feb 21;317(7):693-694. doi: 10.1001/jama.2017.0410.

Relocating abroad. FDA sends staff overseas to help monitor imports.

Mod Healthc. 2011 Oct 24;41(43):32.

Missing evidence.

MLO Med Lab Obs. 2008 Oct;40(10):68.

A Review of the Regulatory Framework for Initiation and Acceleration of Patient Access to Innovative Medical Products in Japan.

Clin Pharmacol Ther. 2019 Sep;106(3):508-511. doi: 10.1002/cpt.1383. Epub 2019 Mar 18.

[Benefit assessment of medical services in German health service - legal framework, historical and international perspective].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Mar;58(3):220-6. doi: 10.1007/s00103-014-2104-3.

Product safety and business interests: deja vu..

Ostomy Wound Manage. 2005 Feb;51(2):8-9.

Advisory committees" critical to the FDA's product review process.

FDA Consum. 2004 Jan-Feb;38(1):17-9.

The FDA approval process for medical devices: an inherently flawed system or a valuable pathway for innovation?

J Neurointerv Surg. 2013 Jul;5(4):269-75. doi: 10.1136/neurintsurg-2012-010400. Epub 2012 Jul 4.

The regulation of drugs and biologics: fifty years into the future.

Food Drug Law J. 2000;55(1):21-5.

FDA perspective on clinical trial design for cardiovascular devices.

Ann Thorac Surg. 2006 Sep;82(3):773-5. doi: 10.1016/j.athoracsur.2006.07.044.

引用本文的文献

Reforming Food, Drug, and Nutraceutical Regulations to Improve Public Health and Reduce Healthcare Costs.

Foods. 2025 Jun 30;14(13):2328. doi: 10.3390/foods14132328.

THE GORDON WILSON LECTURE: THE ETHICS OF HUMAN GENOME EDITING.

Trans Am Clin Climatol Assoc. 2020;131:99-118.

The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea.

BMC Public Health. 2020 May 27;20(1):797. doi: 10.1186/s12889-020-08929-6.

Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA.

Rheumatol Ther. 2019 Sep;6(3):461-471. doi: 10.1007/s40744-019-00168-5. Epub 2019 Aug 6.

Lessons on Data Collection and Curation From the NFL Injury Surveillance Program.

Sports Health. 2019 Sep/Oct;11(5):440-445. doi: 10.1177/1941738119854759. Epub 2019 Jul 2.

Ethics of Human Genome Editing.

Annu Rev Med. 2019 Jan 27;70:289-305. doi: 10.1146/annurev-med-112717-094629.

Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.

Medicine (Baltimore). 2018 Oct;97(40):e12715. doi: 10.1097/MD.0000000000012715.

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.

JAMA Oncol. 2018 Aug 1;4(8):e180798. doi: 10.1001/jamaoncol.2018.0798. Epub 2018 Aug 9.

Update regarding opportunities for orthopaedic surgeons to contribute to postmarket surveillance of potential safety issues for orthopaedic medical devices marketed in the United States.

Arthroplast Today. 2017 Oct 16;3(4):205-206. doi: 10.1016/j.artd.2017.09.003. eCollection 2017 Dec.

Discussion: The role, position, and function of the FDA-The past, present, and future.

Biostatistics. 2017 Jul 1;18(3):417-421. doi: 10.1093/biostatistics/kxx023.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献